Chemistree investee ImmunoFlex receives Health Canada approval for FLEX 10
by CM Staff
FLEX 10(TM) is an antioxidant, specifically packaged in aluminum blisters to reduce the potential for product oxidation.
VANCOUVER — Chemistree Technology Inc. announces to shareholders that Chemistree investee company ImmunoFlex™, a life sciences company developing clinically validated, pharmaceutical grade natural health products based on advancements in genomics research, announced the approval of FLEX 10™ by Health Canada on Jan. 19.
“At ImmunoFlex, we work with the immune system to strengthen, support, and enhance our body’s natural surveillance and response system.” said ImmunoFlex CEO Chris Wagner. “FLEX 10 is the first product in our line up of products designed to achieve this goal so we could not be more delighted with the Health Canada approval.”
Chemistree president Karl Kottmeier commented “This is great news. We view the approval from Health Canada as a significant milestone for Immunoflex and look forward to announcing further advancements for this and their other products.”
FLEX 10(TM) is an antioxidant, specifically packaged in aluminum blisters to reduce the potential for product oxidation.
